AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Niemann-Pick Disease

Recent research efforts aimed at curing Niemann-Pick Disease.

Last updated

Niemann-Pick Disease

Overview

“Niemann-Pick disease” describes several inherited lysosomal storage disorders—conditions in which cells cannot properly process certain fats inside lysosomes, their recycling compartments. Historically named types A and B are now usually called acid sphingomyelinase deficiency (ASMD), caused by changes in SMPD1; type A is a severe infantile neurovisceral form, type B is usually a later-onset visceral form, and an intermediate A/B form can involve the nervous system. Untreated infantile neurovisceral ASMD typically causes relentless developmental loss and death before age three, whereas type B and some A/B presentations can extend into adulthood. ASMD GeneReviews (ncbi.nlm.nih.gov)

Niemann-Pick type C (NPC) is genetically and biologically distinct: variants in NPC1 or NPC2 disrupt movement of cholesterol and other lipids within cells, producing a highly variable but progressive disorder that can affect the liver, lungs, movement, swallowing, cognition, and psychiatric health. Care remains multidisciplinary, including nutritional, respiratory, physical, speech, and palliative support; disease-modifying treatment now includes FDA-approved arimoclomol plus miglustat for eligible people with NPC, levacetylleucine for neurological manifestations of NPC, and olipudase alfa for non-central-nervous-system ASMD manifestations. None is a cure or reliably reverses established neurological injury. NPC clinical-management guidelines FDA: Miplyffa FDA: Aqneursa FDA: Xenpozyme (pmc.ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research activity has accelerated substantially since 2020, especially in NPC, where trials have delivered the first U.S. approvals for neurological treatment and where cyclodextrin, protein-folding, and repurposed-drug strategies are being tested alongside gene-replacement platforms. The dominant questions are whether treatment can reach the brain early enough, whether stored lipids can be safely cleared without harming hearing or other organs, and whether a single gene-delivery treatment can correct both neurological and visceral disease. The field is closer to disease modification than to a durable cure: approved therapies can slow or improve selected manifestations, but human gene replacement or gene editing has not yet reached clinical proof of cure. FDA: Miplyffa FDA: Aqneursa AAV-NPC1 mouse study AAV-NPC2 mouse study (fda.gov)

Major Breakthroughs and Emerging Therapies

For ASMD, the clearest recent therapeutic advance is enzyme replacement with olipudase alfa (Xenpozyme), an infused recombinant acid sphingomyelinase enzyme. The FDA approved it on August 31, 2022 for non-central-nervous-system manifestations in adults and children. Final five-year ASCEND data in adults with chronic ASMD reported sustained improvements in lung diffusion capacity, liver and spleen enlargement, blood lipids, and disease biomarkers; plasma lysosphingomyelin fell by 72% from baseline to final assessment. This is a major advance for visceral disease, but the enzyme does not address central-nervous-system disease in severe type A or neurovisceral A/B ASMD and therefore is not curative. FDA: Xenpozyme ASCEND final results ASMD GeneReviews (fda.gov)

For NPC, arimoclomol and levacetylleucine represent the most important recent regulatory breakthroughs. Arimoclomol enhances the cellular heat-shock response, a protein-protection pathway intended to improve lysosomal function. In a 50-participant randomized phase 2/3 trial, disease progression on a five-domain NPC severity scale was lower over 12 months with arimoclomol than placebo; the estimated treatment difference was 1.40 points, corresponding to a reported 65% reduction in annual progression. The FDA approved arimoclomol as Miplyffa on September 20, 2024, in combination with miglustat for neurological manifestations in patients aged two years and older. Arimoclomol phase 2/3 trial FDA: Miplyffa (pubmed.ncbi.nlm.nih.gov)

Levacetylleucine, marketed as Aqneursa, is an oral small molecule intended to improve neurological function rather than correct the underlying lipid-transport defect. In a randomized, double-blind, placebo-controlled crossover phase 3 trial involving 60 people aged four years and older, treatment improved the functional Scale for the Assessment and Rating of Ataxia (fSARA), which measures gait, posture, sitting, and speech-related impairment. The FDA approved Aqneursa on September 24, 2024 for neurological manifestations of NPC in adults and children weighing at least 15 kilograms. These drugs meaningfully expand care, but they are symptomatic or disease-modifying therapies rather than one-time genetic cures. Levacetylleucine phase 3 trial FDA: Aqneursa (nejm.org)

Cyclodextrins remain a leading lipid-clearance approach for NPC. Hydroxypropyl-beta-cyclodextrin is designed to mobilize trapped cholesterol; in a small 48-week phase I/II intravenous study of Trappsol Cyclo, eight of nine completers improved in at least two domains of the 17-domain NPC Clinical Severity Scale. However, the small sample and absence of a definitive efficacy comparison mean that the result is preliminary. Intrathecal and intravenous cyclodextrin programs have also raised practical safety questions, particularly hearing effects, making dose, route, and long-term monitoring central to development. Trappsol Cyclo phase I/II trial Long-term intrathecal cyclodextrin study (pubmed.ncbi.nlm.nih.gov)

Gene replacement is the most explicitly curative-oriented experimental strategy, because it aims to restore the missing NPC1 or NPC2 function rather than repeatedly manage downstream lipid accumulation. In NPC1 mice, an adeno-associated virus (AAV) vector using a compact NPC1 promoter improved gene-therapy expression and disease measures. In an NPC2 mouse model, a brain-endothelial-targeted AAV-BR1 vector delivering NPC2 improved neurological symptoms and lipid deposition in higher-responding animals. These are important proof-of-concept studies, but they remain preclinical and have not established safety, dose, durability, or effectiveness in people. AAV-NPC1 mouse study AAV-NPC2 mouse study (pubmed.ncbi.nlm.nih.gov)

Additional small-molecule work is exploring repurposing. A 2025 open-label study of low-dose efavirenz, an established antiviral medicine, enrolled 16 genetically confirmed NPC participants receiving standard care including miglustat; investigators reported no efavirenz-related serious adverse events and results consistent with slower progression, especially when treatment began earlier. Because this was a small, uncontrolled study, it is a promising signal rather than proof of efficacy. Efavirenz NPC study (pubmed.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

The pivotal recent NPC trials have already changed the treatment landscape. Orphazyme’s multinational phase 2/3 NPC-002 study tested arimoclomol in 50 children and adolescents, with routine care maintained and many participants receiving miglustat; the randomized phase showed less progression than placebo, and the later open-label extension reported sustained slowing of measured progression without new major safety signals. IntraBio’s phase 3 levacetylleucine trial enrolled 60 patients in a randomized crossover design and supported the September 2024 FDA approval of Aqneursa. Arimoclomol phase 2/3 trial Arimoclomol extension study Levacetylleucine phase 3 trial (pubmed.ncbi.nlm.nih.gov)

Cyclo Therapeutics’ TransportNPC study, NCT04860960, is a randomized, placebo-controlled phase 3 trial of intravenous Trappsol Cyclo plus standard care in NPC1. The registry lists 94 enrolled participants and a planned 96-week blinded period followed by an open-label extension; however, the record’s current status is “unknown,” with the last known status “active, not recruiting” and a last sponsor verification in September 2023. The International Niemann-Pick Disease Alliance’s trial tracker describes the study as completed with data being evaluated, so definitive peer-reviewed phase 3 outcomes should be awaited rather than inferred. TransportNPC registry record INPDA trial tracker (clinicaltrials.gov)

For ASMD, Sanofi/Genzyme’s ASCEND study was a randomized phase 2/3 trial of olipudase alfa in adults, followed by long-term extension treatment. The trial program supported U.S. approval and has now provided up to five years of follow-up showing persistent visceral and pulmonary benefit, but it does not solve the neurological disease that drives the most severe infantile forms. ASCEND trial record ASCEND final results (clinicaltrials.gov)

Methodologies and Scientific Approaches

Researchers combine disease-specific animal models, patient-derived cell systems, biomarker studies, and clinical severity scales. Mouse models allow investigators to test whether AAV vectors can deliver NPC1 or NPC2 broadly enough to improve survival, movement, lipid storage, and vulnerable neurons. Human induced-pluripotent-stem-cell-derived neurons and brain organoids provide complementary systems for studying cholesterol accumulation, lysosomal dysfunction, and drug response in human cells carrying NPC mutations. AAV-NPC1 mouse study Human iPSC neuronal model NPC brain-organoid model (pubmed.ncbi.nlm.nih.gov)

Delivery remains a central scientific problem. AAV gene therapy must reach the brain and peripheral organs while avoiding immune neutralization and dose-related toxicity; a 2025 study of 22 people with NPC1 found that more than half lacked detectable neutralizing antibodies to AAV2 or AAV9 at the study threshold, supporting—but not proving—the feasibility of future AAV treatment. Trials also rely on functional measures such as fSARA and NPC clinical-severity scales, alongside imaging, lung function, liver and spleen volume, and lipid biomarkers to detect meaningful biological and clinical change. AAV antibody study NPC clinical-management guidelines ASCEND final results (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

The field is driven by international specialist centers and public-private collaborations. The arimoclomol trial involved centers including Mayo Clinic, Great Ormond Street Hospital, University College London, Vall d’Hebron University Hospital, Bambino Gesù Children’s Hospital, and other European and U.S. rare-disease centers; the levacetylleucine program was sponsored by IntraBio, while cyclodextrin development has involved Cyclo Therapeutics, Beren Therapeutics, Washington University, and NIH-linked investigators. AAV research has included groups at the U.S. National Institutes of Health and Aalborg University in Denmark. Arimoclomol phase 2/3 trial TransportNPC registry record AAV-NPC2 mouse study (pubmed.ncbi.nlm.nih.gov)

Patient organizations remain unusually important funders because the diseases are ultra-rare. The National Niemann-Pick Disease Foundation reports funding more than 50 grants and 22 fellowships totaling over $4 million since 1993, including one-year fellowships of $40,000. The FDA’s Rare Neurodegenerative Disease Grants Program also reported approximately $4.1 million in fiscal year 2024 support for ongoing projects across several rare neurodegenerative diseases, including NPC; that amount is a program-wide figure, not an NPC-specific award total. NNPDF research funding FDA rare-neurodegenerative-disease grants (nnpdf.org)

Strengths, Limitations, and Challenges

The strongest recent evidence is for disease modification: olipudase alfa has durable visceral benefit in ASMD, while arimoclomol and levacetylleucine provide the first FDA-approved options for neurological NPC. The field also has increasingly useful outcome measures, international registries, disease biomarkers, and patient-derived models. Earlier treatment is likely to be more valuable because therapies may prevent further cell injury better than they restore neurons already lost. ASCEND final results FDA: Miplyffa FDA: Aqneursa (pmc.ncbi.nlm.nih.gov)

The central limitations are incomplete brain delivery, irreversible neurological injury, small trial populations, heterogeneous disease course, and the difficulty of selecting endpoints that matter across infants, children, and adults. Enzyme replacement does not cross sufficiently into the central nervous system for neurovisceral ASMD; cyclodextrin’s optimal route and long-term hearing safety remain unsettled; and AAV therapy must overcome immune responses, durable expression requirements, and the challenge of treating both brain and body. Access is also likely to be constrained by specialized monitoring, repeated infusions or procedures, and the high cost typical of rare-disease therapies. ASMD GeneReviews Long-term intrathecal cyclodextrin study AAV antibody study (ncbi.nlm.nih.gov)

Outlook and Future Directions

As of October 25, 2026, Niemann-Pick research has moved from largely supportive care toward measurable disease modification, but a proven cure remains out of reach. The most important milestones to watch are peer-reviewed results from TransportNPC and other cyclodextrin studies; longer-term real-world outcomes with Miplyffa, Aqneursa, and Xenpozyme; validation of biomarkers that can detect treatment response early; and translation of AAV-based NPC1/NPC2 replacement from animal studies into carefully designed first-in-human trials. A true cure will probably require early diagnosis plus a treatment that durably corrects the causal defect in both the nervous system and peripheral organs. TransportNPC registry record AAV-NPC1 mouse study AAV-NPC2 mouse study (clinicaltrials.gov)

References

Don't see your disease? Request a report